Cargando…

Oral Immunotherapy in Food Allergy: Where Are We Now?

Food allergy (FA) has become more prevalent and problematic in the last 2 decades, and it poses important individual, social, and economic burdens. Besides treating reactions induced by accidental exposure and periodic evaluation for acquiring natural tolerance, the primary management approach is st...

Descripción completa

Detalles Bibliográficos
Autores principales: Özdemir, Pınar Gökmirza, Sato, Sakura, Yanagida, Noriyuki, Ebisawa, Motohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079524/
https://www.ncbi.nlm.nih.gov/pubmed/37021501
http://dx.doi.org/10.4168/aair.2023.15.2.125
_version_ 1785020743000522752
author Özdemir, Pınar Gökmirza
Sato, Sakura
Yanagida, Noriyuki
Ebisawa, Motohiro
author_facet Özdemir, Pınar Gökmirza
Sato, Sakura
Yanagida, Noriyuki
Ebisawa, Motohiro
author_sort Özdemir, Pınar Gökmirza
collection PubMed
description Food allergy (FA) has become more prevalent and problematic in the last 2 decades, and it poses important individual, social, and economic burdens. Besides treating reactions induced by accidental exposure and periodic evaluation for acquiring natural tolerance, the primary management approach is still allergen avoidance as a global standard. However, an active therapeutic approach that can raise the reaction threshold or accelerate tolerance is needed. This review aimed to provide an overview and the latest evidence of oral immunotherapy (OIT), which has recently been used in the active treatment of FA. FA immunotherapy, particularly OIT, is gaining considerable interest, and substantial effort has been made to integrate this active treatment into clinical practice. Consequently, growing evidence has been obtained regarding the efficacy and safety of OIT, particularly for allergens such as peanuts, eggs, and milk. However, several issues need to be addressed regarding the availability, safety, and long-term effects of this intervention. In this review, we summarize currently available information regarding tolerance-inducing immune mechanisms of OIT, data on efficacy and safety, gaps in current evidence, and ongoing research to develop new therapeutic molecules in order to enhance safety.
format Online
Article
Text
id pubmed-10079524
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
record_format MEDLINE/PubMed
spelling pubmed-100795242023-04-08 Oral Immunotherapy in Food Allergy: Where Are We Now? Özdemir, Pınar Gökmirza Sato, Sakura Yanagida, Noriyuki Ebisawa, Motohiro Allergy Asthma Immunol Res Review Food allergy (FA) has become more prevalent and problematic in the last 2 decades, and it poses important individual, social, and economic burdens. Besides treating reactions induced by accidental exposure and periodic evaluation for acquiring natural tolerance, the primary management approach is still allergen avoidance as a global standard. However, an active therapeutic approach that can raise the reaction threshold or accelerate tolerance is needed. This review aimed to provide an overview and the latest evidence of oral immunotherapy (OIT), which has recently been used in the active treatment of FA. FA immunotherapy, particularly OIT, is gaining considerable interest, and substantial effort has been made to integrate this active treatment into clinical practice. Consequently, growing evidence has been obtained regarding the efficacy and safety of OIT, particularly for allergens such as peanuts, eggs, and milk. However, several issues need to be addressed regarding the availability, safety, and long-term effects of this intervention. In this review, we summarize currently available information regarding tolerance-inducing immune mechanisms of OIT, data on efficacy and safety, gaps in current evidence, and ongoing research to develop new therapeutic molecules in order to enhance safety. The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2023-03-31 /pmc/articles/PMC10079524/ /pubmed/37021501 http://dx.doi.org/10.4168/aair.2023.15.2.125 Text en Copyright © 2023 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Özdemir, Pınar Gökmirza
Sato, Sakura
Yanagida, Noriyuki
Ebisawa, Motohiro
Oral Immunotherapy in Food Allergy: Where Are We Now?
title Oral Immunotherapy in Food Allergy: Where Are We Now?
title_full Oral Immunotherapy in Food Allergy: Where Are We Now?
title_fullStr Oral Immunotherapy in Food Allergy: Where Are We Now?
title_full_unstemmed Oral Immunotherapy in Food Allergy: Where Are We Now?
title_short Oral Immunotherapy in Food Allergy: Where Are We Now?
title_sort oral immunotherapy in food allergy: where are we now?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079524/
https://www.ncbi.nlm.nih.gov/pubmed/37021501
http://dx.doi.org/10.4168/aair.2023.15.2.125
work_keys_str_mv AT ozdemirpınargokmirza oralimmunotherapyinfoodallergywherearewenow
AT satosakura oralimmunotherapyinfoodallergywherearewenow
AT yanagidanoriyuki oralimmunotherapyinfoodallergywherearewenow
AT ebisawamotohiro oralimmunotherapyinfoodallergywherearewenow